Xeris Pharmaceuticals | XERS - Cash And Equivalent



Xeris Pharmaceuticals reported $59.28M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Adcock Ingram Holdings ZAR 79.14M 10.28M Dec/2024
Celltrion KRW 829.07B 829.07B Mar/2025
Cspc Pharmaceutical 6.78B 1.6B Dec/2024
Dianthus Therapeutics USD 13.24M 9.56M Jun/2025
Divis Laboratories Ltd 4.15B 31.87B Mar/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Kangmei Pharma CNY 894.14M 120.63M Mar/2025
Knight Therapeutics CAD 5.81M 3.59M Sep/2024
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Medical Developments International AUD 17.62M 7.88M Dec/2024
Neuren Pharmaceuticals AUD 3.15M 582K Dec/2024
Organigram Holdings 35.88M 8.42M Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pharma Mar EUR 21.59M 38.7M Jun/2025
Qiagen NV USD 733.82M 95.06M Jun/2025
Sartorius EUR 819M 20.5M Jun/2025
Sino Biopharmaceutical CNY 3.38B 2.09B Dec/2024
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
Tilray USD 189.7M 15.49M Nov/2024
Zz Pientze Pharmaceu 1.39B 93.82M Mar/2025